![]() |
|
February 1, 2009 to February 7, 2009 (Week 5) |
Overall influenza activity in Canada continues to increase
During week 05, influenza activity in Canada continued to increase with one region reporting widespread influenza activity (in BC) and more regions reporting localized (n=11; in BC, AB, MB, ON, QC, NB & NL) and sporadic activity (n=29) (see map). The proportion of tests that were positive for influenza continued to increase (percentage positive = 11.7%; 568/4,865) (see table). Although the majority of influenza virus detections to date this season were influenza A viruses (57% or 1,003/1,746) detections for influenza B viruses are also increasing (see graph). This week, the ILI consultation rate declined to 21 ILI consultations per 1,000 patient visits (see ILI graph) which is below the expected range. The sentinel response rate was 64%. In week 05, 23 new influenza outbreaks were reported: 6 in LTCFs (AB, ON & QC), 1 in a hospital (NL) and 16 in schools (BC, AB, MB &NB).
Antigenic Characterization:
Since 1 September 2008, the NML has antigenically characterized 290 influenza viruses: 76 influenza A/Brisbane/59/2007(H1N1)-like (from BC, AB, SK, ON, QC, NS & PEI), 29 influenza A/Brisbane/10/2007(H3N2)-like (from BC, AB, SK, ON, QC, PEI & NL), 6 influenza B/Florida/4/2006-like (from AB, ON & QC) and 179 B/Malaysia/2506/2004-like (in all provinces except BC). A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2) and B/Florida/4/2006 are the influenza A and influenza B components recommended for the 2008-09 influenza vaccine. B/Malaysia/2506/2004 was the influenza B component for the 2007-2008 season vaccine (see pie chart).
*** The WHO recommends that the vaccines to be used in the 2009-2010 season (northern hemisphere) contain the following: an A/Brisbane/59/2007 (H1N1)-like virus; an A/Brisbane/10/2007 (H3N2)-like virus; and a B/Brisbane/60/2008-like virus.
Antiviral Resistance:
Results from the NML:
Since the start of the season, the NML has tested 101 influenza A isolates (54 H1N1 and 47 H3N2) for amantadine resistance. All of the H1N1 isolates were susceptible; however all of the H3N2 isolates were resistant to amantadine (resistance = 100% or 47/47). The resistant isolates were from BC, AB, SK, ON, QC, PEI, NL & NT.
The NML has also tested 180 influenza isolates (52 A/H1N1, 17 A/H3N2 & 111 B) for oseltamivir (Tamiflu) resistance. All of the A/H3N2 and B isolates were sensitive; however all of the A/H1N1 isolates were resistant to oseltamivir due to the H274Y mutation (resistance = 100% or 52/52). The resistant isolates were from BC, AB, SK, ON, NS & PEI.
All 175 influenza isolates (45 A/H1N1, 18 A/H3N2 & 112 B) tested for zanamivir resistance to date were sensitive to zanamivir.
Oseltamivir resistance findings from Provincial laboratories:
To date this season, 76 influenza isolates in BC have been sub-typed as A/H1 and were assessed genotypically for oseltamivir resistance using an SNP assay. Sixty-eight isolates tested positive for the H274Y mutation (resistance = 100% or 68/68), with the other 8 specimens still pending confirmatory testing.
Influenza-associated Paediatric Hospitalizations:
In week 05, 29 laboratory-confirmed influenza-associated paediatric hospitalizations were reported through the Immunization Monitoring Program Active (IMPACT) network. The cases were from BC, AB, ON & QC and 72% were due to influenza A. To date, 91 hospitalizations have been reported of which 73% (66/91) have been due to influenza A. The proportion of cases to date by age group are as follows: 19% were 0-5 month olds; 16% were 6-23 month olds; 14% were 2-4 year-olds; 14% were 5-9 year-olds; and 36% were 10-16 year-olds. The distribution of cases to date by province are as follows:8% from BC, 8% from AB, 68% from ON, 14% from QC & 2% from NS.
CDC: During week 04, influenza activity continued to increase in the United States; 792 (16.2%) specimens tested positive for influenza, of which 85% were influenza A and 15% were influenza B. Testing for antiviral resistance indicated that of the influenza A/H1N1, 97.4% were resistant to oseltamivir and 1.1% resistant to amantadine. Of the influenza A/H3N2 viruses tested for resistance, 100% were resistant to amantadine. All tested viruses remain sensitive to zanamivir. One influenza-associated pediatric death was reported during week 04.
EISS: Influenza activity continues to increase in eastern Europe, however in western Europe it is generally decreasing. Influenza A(H3N2) continues to be the dominant influenza virus circulating in Europe. Of the 115 A(H3N2) isolates that were tested for adamantanes susceptibility, 115 (100%) were resistant. Of the 110 A(H1N1) virus isolates tested for resistance against neuraminidase inhibitors, 107 (97%) were resistant to oseltamivir, but all were sensitive to zanamivir.
Human Avian Influenza: Since 7 February 2009, the WHO has reported 2 new cases of human H5N1 avian influenza infection from Egypt and Viet Nam.
| Province
of reporting laboratories |
Report Period: February 1, 2009 to February 7, 2009 |
Season to Date: August 24, 2008 to February 7, 2009 |
||||||
| Total
# Influenza Tests |
# of Positive Tests | Total
# Influenza Tests |
# of Positive Tests | |||||
| Influenza A | Influenza B | Total | Influenza A | Influenza B | Total | |||
NL |
25 | 4 | 1 | 5 | 299 | 8 | 3 | 11 |
PE |
16 | 3 | 0 | 3 | 109 | 8 | 4 | 12 |
NS |
72 | 9 | 6 | 15 | 463 | 14 | 11 | 25 |
NB |
103 | 20 | 3 | 23 | 486 | 27 | 18 | 45 |
QC |
1505 | 136 | 68 | 204 | 12774 | 369 | 98 | 467 |
ON |
1546 | 68 | 120 | 188 | 15285 | 214 | 451 | 665 |
MB |
90 | 1 | 2 | 3 | 1207 | 1 | 4 | 5 |
SK |
252 | 2 | 8 | 10 | 2478 | 19 | 13 | 32 |
AB |
1080 | 45 | 13 | 58 | 11532 | 177 | 98 | 275 |
BC |
176 | 36 | 23 | 59 | 1300 | 166 | 43 | 209 |
Canada |
4865 | 324 | 244 | 568 | 45933 | 1003 | 743 | 1746 |
Specimens from NT, YT, and NU are sent to reference laboratories in other provinces.
Note: Cumulative data includes updates to previous weeks; due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.
Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU)
Respiratory virus laboratory detections in Canada, by geographic
regions, are available weekly on the following website:
<http://www.phac-aspc.gc.ca/bid-bmi/dsd-dsm/rvdi-divr/index-eng.php>

![]()
† sub-regions within the province or territory as defined by the provincial/territorial epidemiologist. Graph may change as late returns come in.
Note: Influenza activity levels, as represented on this map, are assigned and reported by Provincial and Territorial Ministries of Health, based on laboratory confirmations, sentinel ILI rates (see graphs and tables) and outbreaks. Please refer to detailed definitions. For areas where no data is reported, late reports from these provinces and territories will appear on the FluWatch website. Select single maps by report week to get this updated information.
<http://dsol-smed.phac-aspc.gc.ca/dsol-smed/fluwatch/fluwatch.phtml?lang=e>
Click on the map to view provinces/territories and maps for other weeks.


![]()

{Strain characterization, number identified, per cent of total number}
NACI recommends that the trivalent vaccine for the 2008-2009 season in Canada contain
A/Brisbane/59/2007 (H1N1)-like virus; an A/Brisbane/10/2007 (H3N2)-like virus; and a B/Florida/4/2006-like virus.

![]()
Note: No data available for mean rate in previous years for weeks 19 to 39 (1996-1997 through 2002-2003 seasons).

![]()
Please note that the above graphs may change as late returns come in.
To share this page just click on the social network icon of your choice.